Home > Boards > US OTC > Miscellaneous >

Therapeutic Solutions International, Inc. (TSOI)

Add TSOI Price Alert      Hide Sticky   Hide Intro
Moderator: centsability4me
Search This Board: 
Last Post: 1/16/2018 7:17:17 AM - Followers: 81 - Board type: Free - Posts Today: 0

A public clinical stage company focused on immune modulation for the treatment of cancer and other specific diseases.

The Company’s corporate website is  New products can be viewed on : , and ordered here :

Therapeutic Solutions Subsidiary, SandBox Dental Labs, files 510(k) with FDA

Therapeutic Solutions International Announces Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Therapeutic Solutions files Patent on Methods of Re-Activating Dormant Memory Cells with Anticancer Activity

Therapeutic Solutions International Announces Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Therapeutic Solutions files new Patent on Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof

Therapeutic Solutions International Announces Exclusive Patent License Agreement to innaMune with its Subsidiary Emvolio, Inc.

Therapeutic Solutions files Patent on Blood Derived Innate Immune System Stimulator

Therapeutic Solutions International Announces Exclusive Patent License Agreement with its Subsidiary Emvolio, Inc.

Therapeutic Solutions files new Patent on Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants

Therapeutic Solutions International Announces Appointment of Dr. Thomas E. Ichim to its Subsidiary Emvolio, Inc.

Therapeutic Solutions International's Subsidiary, Emvolio, Inc., Files Investigational New Drug Application for StemVacs Cancer Immunotherapy

Therapeutic Solutions International Announces Filing of new Immunotherapy Patent and Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Therapeutic Solutions Receives Allowance on Patent Claim from the US Patent Office Covering ProJuvenol® Active Ingredient Pterostilbene in Cancer Immunotherapies

Therapeutic Solutions International Reports Augmentation of Cancer Immunotherapy Using Pterostilbene
Share Structure - 46M Float
Shares Outstanding 682,751,000 a/o July 31 , 2016
Float 46,312,028 a/o July 31 , 2016
Authorized Shares 995,000,000 a/o July 31 , 2016


Sandbox Dental Labs , Inc.

– is a majority owned subsidiary of TSI consisting of a dental laboratory to manufacture and fill prescriptions from dentists who will use our proprietary Sleep Appliance to treat their patients with mild to moderate obstructive sleep apnea.

Emvolio , Inc .

– is a majority owned subsidiary of TSI where the intellectual property surrounding immune-oncology is housed.  The Company is developing products that can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies.

Omnibiome , Inc .
– is a majority owned subsidiary of TSI where the intellectual property surrounding probiotics is housed. Current programs focus on the use of probiotics to prevent pre-term labor and on using probiotics to reverse periodontal disease.

Nutraceutical Division:
 – TSI has been producing very high quality nutraceuticals. Its flagship product, Projuvenol®, is a Patented (No. 9,682,047) proprietary mixture containing pterostilbene – one of the most potent antioxidants known.

Officers and Directors:

Timothy G. Dixon – President, CEO, & Chairman
Mr. Dixon currently serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc. Mr. Dixon also serves as President and Chairman of OmniBiome, Inc. and President and Chairman of Emvolio, Inc. Mr. Dixon previously served as the President of TMD Courses, Inc. from 2006 to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011. 
Mr. Dixon has attended hundreds of hours of continuing medical/dental education throughout the years and has produced many educational DVD’s used by dental professionals worldwide on the subject of parafunctional control, migraine prevention, therapeutic Botox injections, migraine pathophysiology, dental sleep medicine, and other therapeutic protocols. Mr. Dixon also has extensive experience in dealing with corporate compliance matters with the U.S. Food and Drug Administration, (FDA) as well as many international regulatory bodies.
Gerry B. Berg – Vice President, CFO, Director
Gerry B. Berg has served as our Vice-President and Chief Financial Officer since April 20, 2011.  Mr. Berg also serves as Chief Financial Officer and Director of OmniBiome, Inc. and Chief Financial Officer  and Director of Emvolio, Inc. Mr. Berg became a director of the Company on August 24, 2012.  Mr. Berg has over 30 years of senior management experience working with private and public companies.  From May 2010 to March 2011, Mr. Berg served as President and Chairman of the Board of Directors of Friendly Auto Dealers, Inc., and also served in a consulting capacity from March 2009 to May 2010.
Mr. Berg holds a Bachelors of Science in Accounting from Walsh College where he graduated Cum Laude.  Mr. Berg became a Certified Public Accountant in the State of Michigan in 1979 and in the State of California in 1984.  Mr. Berg does not currently practice as a Certified Public Accountant.
Thomas E. Ichim, Ph.D – Director
Dr. Ichim was appointed to the Board of Directors on January 22, 2016.  Dr. Ichim also serves as Chief Executive Officer of Emvolio, Inc. Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. To date he has published 99 peer-reviewed articles and is co-editor of the textbooks “RNA Interference: From Bench to Clinical Translation” and “Immuno-Oncology Text Book.”
Dr. Ichim is an ad-hoc editor and sits on several editorial boards. Dr Ichim is inventor on over 50 patents and patent applications. Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.
Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, a MSc in Microbiology and Immunology a University of Western Ontario, London, Ontario, Canada and a Ph.D in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.

Hong Ma, MD, Ph.D., M.B.A. – Chief Scientific Officer
Dr. Ma has an extensive history in academic and translational research. Subsequent to completing her medical degree, she performed basic research in the area of molecular biology of endothelial-associated pathways in her doctorate and postdoctoral studies. She has been critical in establishing numerous ventures and collaborations in the area of biosciences. Dr. Ma has over 20 peer-reviewed publications and has worked with prestigious institutions in the USA, China, and Japan. She received her M.D. from Dalian Medical University, her Ph.D in Cardiovascular Pharmacology at Asahikawa Medical College, and has also earned her MBA at the Rady School of Management at the University of California San Diego.

Contact :
CEO email address:  

Therapeutic Solutions International, Inc.
4093 Oceanside Blvd Suite B
Oceanside CA 92056

IR Email:


Disclaimer : All of the information presented in the IBOX , Stickies , or posts of  individual opinions , should not be considered as recommendations to buy , sell , or hold this stock .

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TSOI News: Quarterly Report (10-q) 11/16/2017 01:38:02 PM
TSOI News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 11/14/2017 01:51:33 PM
TSOI News: Therapeutic Solutions International, Inc. strengthens Scientific Advisory Board with the Appointment of Pablo A. Guzman, MD. 10/17/2017 08:20:16 AM
TSOI News: Therapeutic Solutions International, Inc. files new patent for the Synergistic Inhibition of Glioma Using Pterostilbene 10/16/2017 08:53:26 AM
TSOI News: Current Report Filing (8-k) 09/26/2017 02:55:26 PM
#5855   In addition to centsability4me 01/16/18 07:17:17 AM
#5854   TSI has entered into centsability4me 01/15/18 02:53:00 PM
#5853   kirk5 , centsability4me 01/15/18 10:11:38 AM
#5852   cents do you know if their is any kstock 01/14/18 10:28:23 AM
#5851   10:01 - 3 gen 2018. corvatsch 01/07/18 05:28:58 PM
#5850   THANKS CENTS!!! corvatsch 01/05/18 09:17:16 AM
#5849   TSOI update centsability4me 01/04/18 11:11:13 AM
#5848   TSOI centsability4me 12/26/17 12:33:08 PM
#5847   That’s for sure. This is like watching paint Bob842 12/13/17 03:02:30 PM
#5846   no volume, no party !!! corvatsch 12/13/17 01:50:01 PM
#5845   with all of these centsability4me 12/12/17 11:57:34 AM
#5844   MemoryMune centsability4me 12/03/17 08:08:00 AM
#5843   More on MemoryMune : centsability4me 12/03/17 07:58:16 AM
#5842   Thanks CENTS. corvatsch 12/01/17 02:35:24 PM
#5841   DISCUSSION We have established that pterostilbene can potentiate the centsability4me 12/01/17 01:41:24 PM
#5840   Re: pterostilbene centsability4me 12/01/17 12:57:57 PM
#5839   $TSOI when pterostilbene is combined with brain cancer corvatsch 11/29/17 08:37:11 AM
#5838   #TSOI MemoryMune may be capable of overcoming memory corvatsch 11/29/17 08:34:34 AM
#5837   Agreed this one should run here soon. Level Walterwhite666 11/09/17 08:39:43 PM
#5836   All great finds, this is a sleeping giant Rags2Riche$$$$ 11/07/17 08:56:42 AM
#5835   ptero and other forms of cancer centsability4me 11/03/17 01:02:55 PM
#5834   reading up on TSOI , centsability4me 11/03/17 12:32:57 PM
#5833   NEW Seed investor known for biotech Tekidesign 11/03/17 12:24:04 AM
#5832   Plus all of the catalysts it has going Tekidesign 11/03/17 12:22:01 AM
#5831   Chart is setting up for a good technical play!! Tekidesign 11/03/17 12:21:30 AM
#5830   Agreed this one should run hard Walterwhite666 11/02/17 09:09:45 PM
#5829   TSOI centsability4me 11/02/17 01:51:42 PM
#5828   Gonna be a good run here . Allot JH Mcdough 11/01/17 11:09:47 PM
#5827   Should be promising imo Walterwhite666 11/01/17 05:04:21 PM
#5826   TSOI centsability4me 11/01/17 01:34:20 PM
#5825   Basically $1.25M retail investment...My guess with discount probably gotinearly 11/01/17 08:33:21 AM
#5824   John Peck Jr gotinearly 11/01/17 08:31:04 AM
#5823   A nice 13D filed today. Good luck to shanak10 10/31/17 08:42:54 PM
#5822   A biotech angel investor just acquired voting rights Lone Wolf 10/31/17 04:54:20 PM
#5821   the Morpheus centsability4me 10/31/17 02:12:32 PM
#5820   Looks like it’s gapping this morning . This JH Mcdough 10/31/17 09:30:49 AM
#5819   Great things here. I think this is a Walterwhite666 10/31/17 12:29:04 AM
#5818   Recent Patent “combined with brain cancer therapeutics... prognosis Tekidesign 10/30/17 10:48:39 PM
#5817   Really good things happening here! $tsoi should be Walterwhite666 10/30/17 10:35:58 PM
#5816   Sleep apnea treatment!!! HUGE Market!! Tekidesign 10/30/17 10:32:07 PM
#5815   New patents for Tumor & Cancer treatments!! HUGE Tekidesign 10/30/17 10:15:28 PM
#5814   Agreed! I’ve been on bid and haven’t gotten Tekidesign 10/30/17 10:09:46 PM
#5813   Nobody wants to get rid of shares I see Walterwhite666 10/30/17 06:50:44 PM
#5812   $tsoi will run hard just give it time. Walterwhite666 10/29/17 10:36:08 PM
#5811   Really thin level 2 should run here imo Walterwhite666 10/24/17 10:07:49 PM
#5810   FAQ Update centsability4me 10/23/17 10:28:49 AM
#5809   yes , centsability4me 10/19/17 12:30:05 PM
#5808   Our day will come! Soon imo! Rags2Riche$$$$ 10/19/17 11:13:47 AM
#5807   Dr. Guzman bio info : centsability4me 10/17/17 10:20:36 AM
#5806   NEWS 10/17/17 centsability4me 10/17/17 10:15:40 AM